FI112652B - Menetelmä uusien terapeuttisesti käyttökelpoisten indolin-2-onijohdannaisten valmistamiseksi - Google Patents

Menetelmä uusien terapeuttisesti käyttökelpoisten indolin-2-onijohdannaisten valmistamiseksi Download PDF

Info

Publication number
FI112652B
FI112652B FI953866A FI953866A FI112652B FI 112652 B FI112652 B FI 112652B FI 953866 A FI953866 A FI 953866A FI 953866 A FI953866 A FI 953866A FI 112652 B FI112652 B FI 112652B
Authority
FI
Finland
Prior art keywords
group
substituted
unsubstituted
compound
formula
Prior art date
Application number
FI953866A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI953866A (fi
FI953866A0 (fi
Inventor
Takashi Emura
Toru Esaki
Eiichi Hoshino
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of FI953866A publication Critical patent/FI953866A/fi
Publication of FI953866A0 publication Critical patent/FI953866A0/fi
Application granted granted Critical
Publication of FI112652B publication Critical patent/FI112652B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
FI953866A 1993-02-17 1995-08-16 Menetelmä uusien terapeuttisesti käyttökelpoisten indolin-2-onijohdannaisten valmistamiseksi FI112652B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP6729793 1993-02-17
JP6729793 1993-02-17
JP16726293 1993-05-31
JP16726293 1993-05-31
PCT/JP1994/000235 WO1994019322A1 (en) 1993-02-17 1994-02-17 Indolin-2-one derivative
JP9400235 1994-02-17

Publications (3)

Publication Number Publication Date
FI953866A FI953866A (fi) 1995-08-16
FI953866A0 FI953866A0 (fi) 1995-08-16
FI112652B true FI112652B (fi) 2003-12-31

Family

ID=26408486

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953866A FI112652B (fi) 1993-02-17 1995-08-16 Menetelmä uusien terapeuttisesti käyttökelpoisten indolin-2-onijohdannaisten valmistamiseksi

Country Status (19)

Country Link
US (5) US5952511A (sl)
EP (1) EP0685463B1 (sl)
JP (1) JP3419539B2 (sl)
KR (1) KR100226310B1 (sl)
CN (1) CN1046268C (sl)
AT (1) ATE217864T1 (sl)
AU (1) AU6044894A (sl)
CA (1) CA2156287C (sl)
CZ (1) CZ290504B6 (sl)
DE (1) DE69430664T2 (sl)
ES (1) ES2176236T3 (sl)
FI (1) FI112652B (sl)
HU (1) HUT74105A (sl)
MY (1) MY128102A (sl)
NO (1) NO305201B1 (sl)
PL (1) PL176710B1 (sl)
RU (1) RU2128170C1 (sl)
TW (1) TW281669B (sl)
WO (1) WO1994019322A1 (sl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
CN1069314C (zh) * 1993-11-26 2001-08-08 田边制药株式会社 2－氧代二氢吲哚衍生物
WO1995024385A1 (en) * 1994-03-07 1995-09-14 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
WO1997033867A1 (fr) * 1996-03-11 1997-09-18 Ube Industries, Ltd. Procede de preparation de composes d'indole actifs sur le plan optique
AU3459497A (en) * 1996-07-12 1998-02-09 Chugai Seiyaku Kabushiki Kaisha Cancer cell proliferation inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
ATE285396T1 (de) 1998-06-19 2005-01-15 Vertex Pharma Sulfonamide als aspartyl-protease-inhibitoren
WO2000033834A1 (en) * 1998-12-04 2000-06-15 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
US6605623B1 (en) 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
JP4058243B2 (ja) 1999-01-29 2008-03-05 中外製薬株式会社 軟骨形成促進剤およびインドリン−２−オン誘導体
ATE425142T1 (de) * 1999-04-23 2009-03-15 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
DK1233958T3 (da) * 1999-11-23 2011-10-17 Methylgene Inc Hæmmere af histondeacetylase
WO2001066142A1 (fr) * 2000-03-10 2001-09-13 Chugai Seiyaku Kabushiki Kaisha Preparations pour chondrogenese
US7612065B2 (en) 2000-04-21 2009-11-03 Vertex Pharmaceuticals Incorporated Inhibitors of c-JUN N-terminal kinases (JNK)
WO2001098269A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2413418A1 (en) * 2000-06-21 2001-12-27 Joseph B. Santella Piperidine amides as modulators of chemokine receptor activity
JP4897221B2 (ja) 2002-12-20 2012-03-14 チバ ホールディング インコーポレーテッド アミン類の合成及びその合成のための中間体
CN1324009C (zh) * 2003-01-30 2007-07-04 普文英 化合物1－n－甲氧基－2－氧－吲哚－3－乙酰胺及其药物用途
US20080030974A1 (en) * 2006-08-02 2008-02-07 Abu-Ageel Nayef M LED-Based Illumination System
US20090050905A1 (en) * 2007-08-20 2009-02-26 Abu-Ageel Nayef M Highly Efficient Light-Emitting Diode
WO2010090862A2 (en) * 2009-01-21 2010-08-12 Abu-Ageel Nayef M Illumination system utilizing wavelength conversion materials and light recycling
US8987310B2 (en) 2009-10-30 2015-03-24 Merck Sharp & Dohme Corp. Heterocycle amide T-type calcium channel antagonists
CN102516153B (zh) * 2011-12-14 2014-03-12 南京工业大学 5-氟吲哚-2-酮-3-脲类化合物及其制备方法和应用
BR112016011727A2 (pt) 2013-11-22 2017-08-08 CL BioSciences LLC Antagonistas de gastrina para o tratamento e prevenção de osteoporose
KR102161674B1 (ko) * 2014-02-18 2020-10-05 주식회사 대웅제약 이사틴 유도체 및 이의 제조방법
CN113456631B (zh) * 2021-08-06 2022-06-21 徐州医科大学 一种靶向acsl1的小分子药物及其在治疗子宫内膜癌中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
JPS62228072A (ja) * 1985-12-20 1987-10-06 Kissei Pharmaceut Co Ltd ３−アミノインドリン−２−オン誘導体
JPS62234080A (ja) * 1985-12-20 1987-10-14 Kissei Pharmaceut Co Ltd インドリン−２−オン誘導体
US4760083A (en) * 1986-04-10 1988-07-26 E. I. Dupont De Nemours & Company 3,3-disubstituted indolines
JPS62270576A (ja) * 1986-05-19 1987-11-24 Kissei Pharmaceut Co Ltd イサチン誘導体
JPS63156771A (ja) * 1986-12-19 1988-06-29 Kissei Pharmaceut Co Ltd ３−アミノインドリン−２−オン誘導体
JPS62156771A (ja) * 1986-12-19 1987-07-11 Tokyo Shokai:Kk 処方箋処理装置
US4876259A (en) * 1987-01-05 1989-10-24 E. I. Du Pont De Nemours And Company 3,3-disubstituted indolines
EP0442878A4 (en) * 1988-04-05 1991-10-23 Abbott Laboratories Derivatives of tryptophan as cck antagonists
WO1992004038A1 (en) * 1990-08-31 1992-03-19 Warner-Lambert Company Pro-drugs for cck antagonists
WO1992007830A2 (en) * 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
CA2055094A1 (en) * 1990-11-13 1992-05-14 Mark G. Bock Cholecystokinin antagonist
JPH05104510A (ja) * 1991-10-18 1993-04-27 Inax Corp 基板へのモルタル塗布方法

Also Published As

Publication number Publication date
CZ290504B6 (cs) 2002-08-14
CN1046268C (zh) 1999-11-10
PL176710B1 (pl) 1999-07-30
NO953235L (no) 1995-10-09
KR960701011A (ko) 1996-02-24
CN1117727A (zh) 1996-02-28
FI953866A (fi) 1995-08-16
AU6044894A (en) 1994-09-14
CA2156287C (en) 2005-12-27
US6114536A (en) 2000-09-05
ATE217864T1 (de) 2002-06-15
CZ209695A3 (en) 1995-12-13
FI953866A0 (fi) 1995-08-16
EP0685463B1 (en) 2002-05-22
HU9502415D0 (en) 1996-05-28
EP0685463A4 (sl) 1996-01-03
US6207836B1 (en) 2001-03-27
MY128102A (en) 2007-01-31
NO953235D0 (no) 1995-08-17
JP3419539B2 (ja) 2003-06-23
PL310168A1 (en) 1995-11-27
US5952511A (en) 1999-09-14
CA2156287A1 (en) 1994-09-01
HUT74105A (en) 1996-11-28
DE69430664T2 (de) 2003-01-30
NO305201B1 (no) 1999-04-19
RU2128170C1 (ru) 1999-03-27
WO1994019322A1 (en) 1994-09-01
ES2176236T3 (es) 2002-12-01
US6127544A (en) 2000-10-03
TW281669B (sl) 1996-07-21
JPH0748349A (ja) 1995-02-21
US6031111A (en) 2000-02-29
KR100226310B1 (ko) 1999-10-15
DE69430664D1 (de) 2002-06-27
EP0685463A1 (en) 1995-12-06

Similar Documents

Publication Publication Date Title
FI112652B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten indolin-2-onijohdannaisten valmistamiseksi
TWI242004B (en) 1-(1-substituted-4-piperidinyl)methyl-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
EP1105376B1 (en) Oxindole derivatives as growth hormone releasers
NZ249158A (en) N-sulphonyl-2-oxindole derivatives and pharmaceutical compositions
KR20060114382A (ko) 아자비시클릭 유도체, 이의 제조 방법 및 이를 함유하는약제 조성물
RU2591190C2 (ru) Новые 4-амино-n-гидроксибензамиды в качестве ингибиторов hdac для лечения рака
HUT69704A (en) Isatin derivatives, process for the preparation thereof and pharmaceutical compositions comprising the same
IE831730L (en) Quinoline derivatives
SK121397A3 (en) Di-substituted 1,4-piperidine esters and amides having 5-ht4 antagonistic activity, producing method and their use
US5053511A (en) 1,3-dihydro-1-(pyridinylamino)-2h-indol-2-ones
HU198931B (en) Process for producing 2-square brackets open /piperidin-4-yl/-methyl square brackets closed -1,2,3,4-tetradihydro-9h-pyrido/3,4-b/indole derivatives and pharma ceutical compositions comprising same
AU2003226579A1 (en) Azabicyclo derivatives as muscarinic receptor antagonists
MXPA06013629A (es) Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica.
DK157995B (da) Analogifremgangsmaade til fremstilling af indolderivater
UA75060C2 (en) Substituted n-benzyl-indole-3-yl-glyoxylic acid derivatives having antitumor activity, use thereof and pharmaceutical composition based thereon
EP1615634B1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
PT85822B (pt) Processo para a preparacao de derivados de indolo-pirazino-benzodiazepina
KR20050023400A (ko) 무스카린 수용체 길항제로서의 아자비시클로 유도체
MXPA06009346A (en) Novel azabicyclic derivatives, preparation method thereof and pharmaceutical compositions containing same